EN DE
Watch Arbutus Biopharma Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Arbutus Biopharma Corp (ABUS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Arbutus Biopharma Corp stock $3.07, price $3.82, that is 19.6% below the price, quality 49 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA03879J1003

AB Arbutus Biopharma Corp logo Thin data Nov 10, 2026

Arbutus Biopharma Corp

ABUS · US
Expensive, weak quality

Our calculation puts a fair price 20% below what the stock costs today.

Highly profitable · 84.2% net margin (TTM)
Low debt
Ranks above peers (7/11)
Costs just 4.8 times its yearly profit.
Quality 49/100
Moderate moat 61/100 · thin data
Fair value $3.07 · Overvalued
Weak Growth (revenue 3y −28.8 %/yr in USD)
Negative free cash flow
Thin data
Estimate
Watch Arbutus Biopharma Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$5.22 $1.69 Fair Value $3.07 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.69 – $5.22 · fair‑value band $2.30 – $3.84 · the $3.82 price screens above the $3.07 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Arbutus Biopharma in your weekly email

Every Wednesday you see whether Arbutus Biopharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.

Show moreShow less

Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology.

The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Stock analysis

Arbutus Biopharma Corp (ABUS) currently trades at $3.82, while our estimate is $3.07, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.30 (bear) to $3.84 (bull), the price of $3.82 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Arbutus Biopharma Corp reported revenue of $14.1M in FY2025 versus $11.0M in FY2021, a compound +6.4%/yr. Reported net income was −$33.5M in FY2025.

Key figures

Market cap $754M Small · P/E ratio 4.8 · P/S ratio 4.15 · EPS (TTM) $0.7900 · Net margin 84.2% · Return on equity 89.6% · Return on assets (EBIT) −42.0% (5-year average) · Operating margin −567%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −20%, ABUS screens richer than that median.

Fair Value

Bear $2.30 Fair Value $3.07 Bull $3.84
Price $3.82 · Downside -19.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 85
Are margins and returns getting better?
Cashflow 36
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 53
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 35
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 9 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+128.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Start year 2020 (pandemic). Over 10 years: −5.5% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−836.1% (2020) → −192.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ABUS screens overvalued: fair value 20% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Arbutus Biopharma Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −19.6% · Above median
Profitability
Return on equity (12 months) 89.6% · Top 25%
Return on assets −35.4% · Below median
Net margin (12 months) 84.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −90.6% · Bottom 25%
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 4.8× · Cheapest 25%
P/B 9.85× · Priciest 25%
P/S (12 months) 4.15× · Cheaper than median
EV/EBITDA 5.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)92 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ABUS
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ABUS
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ABUS
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ABUS
argenx SE ARGX $971.55 $908.40 −7% vs ABUS
CSL Limited CSL A$201.68 A$181.40 −10% vs ABUS
Moderna, Inc MRNA $250.83 $158.70 −37% vs ABUS
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ABUS
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ABUS
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ABUS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Arbutus Biopharma Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Arbutus Biopharma Corp Fair Value". https://www.fairvalue-calculator.com/stock/ABUS

Frequently asked questions

Is Arbutus Biopharma Corp (ABUS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $3.07 versus a price of $3.82, about 20% lower (overvalued).
What is the fair value of ABUS?
Our estimate for Arbutus Biopharma Corp is $3.07 (as of Nov 10, 2026), built from audited fundamentals. The current price: $3.82.
What is the quality score of ABUS?
Arbutus Biopharma Corp has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arbutus Biopharma Corp (ABUS)?
Our calculated price target is the estimate of $3.07 (as of Nov 10, 2026). Cautious scenario $2.30, optimistic scenario $3.84. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Arbutus Biopharma Corp stock forecast for 2026?
Our estimate puts fair value at $3.07, about 20% lower versus a price of $3.82 (overvalued). Cautious scenario $2.30, optimistic scenario $3.84. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Arbutus Biopharma Corp (ABUS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arbutus Biopharma Corp it is $3.07 per share (as of Nov 10, 2026), against a price of $3.82.
Is Arbutus Biopharma Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ABUS trades above its calculated fair value: price $3.82, fair value $3.07, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ABUS?
No. The price is what the market pays today ($3.82); the fair value is what the company's own numbers justify ($3.07). For Arbutus Biopharma Corp the two are $0.7500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arbutus Biopharma Corp worth?
The market values Arbutus Biopharma Corp at about $754M (market capitalisation, as of Nov 10, 2026). Per share that is $3.82; our models calculate a fair value of $3.07 per share.
What do the bullish and bearish scenarios say about ABUS?
Our models span a range for Arbutus Biopharma Corp: cautious scenario $2.30, base $3.07, optimistic $3.84 per share (as of Nov 10, 2026, price $3.82). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ABUS?
Arbutus Biopharma Corp trades at a price-to-earnings ratio of 4.8 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.07 is built from several models across several years. Other multiples: P/B 9.9, P/S 4.2, EV/EBITDA 5.1.
How solid is the balance sheet of Arbutus Biopharma Corp (ABUS)?
Balance-sheet figures for Arbutus Biopharma Corp (as of Nov 10, 2026): return on equity 89.6%, debt of 0.16 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is ABUS from its 52-week high?
Arbutus Biopharma Corp trades at $3.82, about 27% below its 52-week high of $5.22 and 5% above the low of $3.66 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $3.07 is for.
Which stocks are comparable to Arbutus Biopharma Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arbutus Biopharma Corp stock attractive at the current price?
The data as of Nov 10, 2026: price $3.82, calculated fair value $3.07 (−20%), Quality Score 49/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Arbutus Biopharma Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arbutus Biopharma Corp (ABUS)?
The closing price on Nov 10, 2026 was $3.82. Our estimate is $3.07, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arbutus Biopharma Corp right now?
Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Arbutus Biopharma Corp

How large is the market capitalisation of Arbutus Biopharma Corp (ABUS)?
The market capitalisation of Arbutus Biopharma Corp is $754M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arbutus Biopharma Corp (ABUS)?
The price-to-sales ratio of Arbutus Biopharma Corp is 4.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arbutus Biopharma Corp (ABUS)?
Earnings per share at Arbutus Biopharma Corp are $0.7900 (price ÷ EPS = P/E 4.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Arbutus Biopharma Corp (ABUS)?
The net margin of Arbutus Biopharma Corp is 84.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arbutus Biopharma Corp (ABUS)?
The return on equity (ROE) of Arbutus Biopharma Corp is 89.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arbutus Biopharma Corp (ABUS)?
On an EBIT basis the return on assets of Arbutus Biopharma Corp is −42.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arbutus Biopharma Corp (ABUS)?
The operating margin of Arbutus Biopharma Corp is −567% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arbutus Biopharma Corp (ABUS)?
Revenue at Arbutus Biopharma Corp is growing −90.6% versus a year earlier (3y avg −28.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Arbutus Biopharma Corp (ABUS) generate?
The free cash flow of Arbutus Biopharma Corp is −$39.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Arbutus Biopharma Corp (ABUS) hold?
Arbutus Biopharma Corp holds more cash than debt, $13.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Arbutus Biopharma Corp in the live analysis

One click puts Arbutus Biopharma Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.